A detailed history of Royal Bank Of Canada transactions in Aura Biosciences, Inc. stock. As of the latest transaction made, Royal Bank Of Canada holds 5,740 shares of AURA stock, worth $47,067. This represents 0.0% of its overall portfolio holdings.

Number of Shares
5,740
Previous 5,216 10.05%
Holding current value
$47,067
Previous $39,000 30.77%
% of portfolio
0.0%
Previous 0.0%

Shares

13 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 14, 2024

BUY
$6.9 - $10.36 $3,615 - $5,428
524 Added 10.05%
5,740 $51,000
Q2 2024

Aug 14, 2024

BUY
$6.81 - $7.89 $24,257 - $28,104
3,562 Added 215.36%
5,216 $39,000
Q1 2024

Nov 05, 2024

SELL
$7.09 - $9.24 $25,254 - $32,912
-3,562 Reduced 68.29%
1,654 $12,000
Q1 2024

May 15, 2024

SELL
$7.09 - $9.24 $62,406 - $81,330
-8,802 Reduced 84.18%
1,654 $12,000
Q4 2023

Feb 14, 2024

BUY
$7.02 - $11.98 $35,128 - $59,947
5,004 Added 91.78%
10,456 $92,000
Q3 2023

Nov 14, 2023

BUY
$8.97 - $12.38 $14,226 - $19,634
1,586 Added 41.02%
5,452 $48,000
Q2 2023

Aug 14, 2023

BUY
$8.51 - $13.33 $21,640 - $33,898
2,543 Added 192.21%
3,866 $47,000
Q1 2023

May 15, 2023

SELL
$8.88 - $12.11 $12,059 - $16,445
-1,358 Reduced 50.65%
1,323 $12,000
Q4 2022

Feb 14, 2023

BUY
$9.86 - $14.59 $24,235 - $35,862
2,458 Added 1102.24%
2,681 $28,000
Q3 2022

Nov 14, 2022

BUY
$13.1 - $20.34 $1,572 - $2,440
120 Added 116.5%
223 $4,000
Q2 2022

Aug 15, 2022

SELL
$12.37 - $21.86 $2,993 - $5,290
-242 Reduced 70.14%
103 $1,000
Q1 2022

May 16, 2022

SELL
$15.94 - $23.34 $12,959 - $18,975
-813 Reduced 70.21%
345 $8,000
Q4 2021

Feb 14, 2022

BUY
$14.76 - $24.89 $17,092 - $28,822
1,158 New
1,158 $19,000

Others Institutions Holding AURA

About Aura Biosciences, Inc.


  • Ticker AURA
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 29,273,600
  • Market Cap $240M
  • Description
  • Aura Biosciences, Inc. operates as a biotechnology company that develops therapies to treat cancer. The company develops virus-like drug conjugates (VDC) technology platform for the treat tumors of high unmet need in ocular and urologic oncology. It develops AU-011, a VDC candidate for the treatment of primary choroidal melanoma. It also develop...
More about AURA
Track This Portfolio

Track Royal Bank Of Canada Portfolio

Follow Royal Bank Of Canada and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Royal Bank Of Canada, based on Form 13F filings with the SEC.

News

Stay updated on Royal Bank Of Canada with notifications on news.